Program
tagmokitug
Also written as “CHS-114” and “Tagmokitug”.
Its studies are mostly in Prostatic Neoplasms · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by Coherus Oncology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Coherus Oncology | 33 open or running | phase 2since Nov 13, 2026 | Nov 14, 2022 | Jan 2028phase 1 · NCT06657144 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2022First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT05635643 · 87 enrolled · United States
- Oct 23, 2024Phase 1 study in Neoplasm MetastasisNCT06657144 · 154 planned · United States, Taiwan
- Nov 13, 2026Phase 2 study in Prostatic NeoplasmsPhase 2 reachedNCT07945821 · 12 planned · United States
Ahead
- Jan 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT06657144
- Aug 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT07945821
TargetBeta
“A human immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule
Other programs on CCR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cafelkibart | Sino Biopharmaceutical | phase 3 | 7 |
| CCR8 Inhibitor IPG7236rule | nanjing-immunophage-biotech-co-ltd | phase 2 | 3 |
| denikitugrule | Gilead Sciences | phase 2 | 3 |
| imzokitug | Bristol-Myers Squibb | phase 2 | 2 |
| Anti-CCR8 Antibody-drug Conjugate TAK-188rule | Takeda | phase 2 | 1 |
| Anti-CCR8 Monoclonal Antibody HC006rule | hc-biopharma-inc | phase 1 | 2 |
| azirkitug | AbbVie | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07945821Prostatic Neoplasms · United States | 2 | Recruiting | Aug 2028 | 12 |
| NCT06657144Neoplasm Metastasis · United States, Taiwan | 1 | Recruiting | Jan 2028 | 154 |
| NCT05635643Squamous Cell Carcinoma of Head and Neck · United States | 1 | Active, not recruiting | Sep 30, 2026 | 87 |
How it is read
Names in the registry
- “CHS-114”, 2 entries
- “Tagmokitug”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.